Advertisement

Topics

Latest Immunology NewsRSS

10:31 EDT 20th September 2017 | BioPortfolio

World Cancer-treating Drugs Market Forecast 2017-2027

LONDON, September 20, 2017 /PRNewswire/ -- Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the second half of the forecast period. The market reached $102bn in 2016, dominated by the immunotherapy segment which held 44.1% share of the market.    &n

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy

SAN FRANCISCO, Sept. 20, 2017 /PRNewswire-USNewswire/ -- The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) today announced the first patients have begun treatment in a new pancreatic cancer multi-center clinical trial. To combat the nation's third deadliest cancer, the phase 1b/2 open-label study will explore the combination of standard chemotherapy and two...

#jobs #lifescience Associate Specialist, Step I-II â Microbiology, Immunology â Molecular and Cell Biology

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Associate Specialist, Step I-II â Microbiology, Immunology â Molecular and Cell Biology .Associate Specialist, Step I-II â Microbiology, Immunology â Molecular and Cell Biology The Portnoy lab in … Continue reading → Cet article #jobs #lifescience Associate Spe...

Irvine Scientific Introduces Chemically-Defined Dendritic Cell Culture Medium for Immunotherapy Applications.

Dendritic cells are a key contributor to developing cancer vaccines SANTA ANA, California – September 19th, 2017: Irvine Scientific, a world leader in cell culture media development and manufacture, today announced the introduction of PRIME-XV® Dendritic Cell Maturation CDM, a chemically-defined, animal component-free medium for the differentiation of monocytes into immature dendr...

FluGen Announces Expanded Role for Clinical Advisory Board: Dr. Robert Belshe to Chair

Today FluGen Inc., a clinical stage vaccine company, announced that Dr. Robert Belshe was named Chairman of the Company’s Clinical Advisory Board (CAB). Along with Dr. Belshe’s appointment, FluGen is expanding the roles of all members of the CAB to guide the Company through the clinical development of RedeeFlu™. The Company is focused on the developm...

Irvine Scientific Introduces Chemically-Defined Dendritic Cell Culture Medium for Immunotherapy Applications

Dendritic cells are a key contributor to developing cancer vaccines Irvine Scientific, a world leader in cell culture media development and manufacture, today announced the introduction of PRIME-XV® Dendritic

Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced two abstracts were selected for presentation at the 32nd annual Society for Immunotherapy of Cancer

Maternal Smoking, Stress Levels and Depression Shown to be Strong Risk Factors For Asthma in Inner-city Children, Not Exposure to Allergens

In a study published in the AAAAI’s journal, The Journal of Allergy and Clinical Immunology, researchers set out to find which inner-city environmental exposures positively or negatively affect the rate of asthma. Milwaukee, WI (PRWEB) September 19, 2017 Environmental exposures in early life appear to play an important role in the development of asthma, and children living in the inner-city are...

Enlivex Therapeutics Announces Closing of USD 8 Million Series B Round Led by KOREA INVESTMENT PARTNERS (KIP) and HADASIT BIO HOLDINGINGS LTD. (HBL)

JERUSALEM, September 19, 2017 /PRNewswire/ -- Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, announced today the closing of an $8 million equity financing round at a valuation of approximately $50 Million pre-closing. Korea Investment Partners (KIP) has invested USD 6 million in the financing round, and Hadasit Bio Holdingings Ltd. (HBL) (TASE:HDST) has co-invested USD ...

Flu Shots: Here We Go Again!

The many myths about flu shots continue to circulate and persuade some people not to get a flu shot. Flu shots are excellent insurance, safe and reasonably effective. Immunization protects not only the recipient but also vulnerable groups in the community.

Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that data for its drug candidate CB-839, an orally bioavailable glutaminase...

Incysus Submits Investigational New Drug (IND) Application for Allogeneic Gamma-Delta T Cell Immunotherapy for Leukemia and Lymphoma

NEW YORK, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced the submission of an IND application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 study of expanded and activated allogeneic γδ T cells for patients with blo...

Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA

Data to highlight recent preclinical studies of SB 11285, a novel next-generation STING agonist HOPKINTON, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced a planned poster present...

Kiadis Pharma: Cellular Immunotherapy Presentation At Conference Review Of Phase I And II ATIR101 Data

AMSTERDAM-DUIVENDRECHT, The Netherlands--(BUSINESS WIRE)--Regulatory News: Kiadis Pharma N.V. (Kiadis Pharma or the Company) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow...

#jobs #lifescience Henry M Jackson Foundation: Postdoctoral Fellow I

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Henry M Jackson Foundation: Postdoctoral Fellow I . Competitive Pay: Henry M Jackson Foundation: Henry M Jackson is seeking a Postdoctoral Fellow with expertise in immunology and microbiology. … Continue reading → Cet article #jobs #lifescience Henry M Jackson Foun...

Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Anthony Lombardo, interim chief executive officer, will present a company overview at the Cantor Fitzgerald Global Healthcare Conference being held Sept. 25-27, 2017 in New York. The con...

Formula Pharmaceuticals Announces Initiation of the First Clinical Trial for Allogeneic CIK-CAR Cancer Immunotherapy

Formula Pharmaceuticals, Inc. (“Formula”) announced today the opening of the first clinical trial for allogeneic Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) cancer immunotherapy. This open-label, dose-escalating clinical Phase 1/2a trial will evaluate the safety, pharmacokinetics (PK), and antitumor activity of modifie...

Sanford Burnham Prebys Medical Discovery Institute Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23082017] Prices from USD $250

SummarySanford Burnham Prebys Medical Discovery Institute Sanford Burnham is a nonprofit public benefit institute that offers medical research services. The institute offers research programs in the field of tumor initiation and maintenance, cancer metabolism and signaling networks, tumor microenvironment and cancer immunology, degenerative diseases, immunity and pathogenesis, human genetics devel...

Cell Medica Appoints CSO to Accelerate R&D for CAR and TCR Programmes

Cell Medica (or ‘the Company’), a leader in cell-based immunotherapies for the treatment of cancer, today announced the appointment of Luis Borges, PhD, as Chief Scientific Officer. Luis will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twent...

Formula Pharmaceuticals, Inc. Announces Initiation Of The First Clinical Trial For Allogeneic CIK-CAR Cancer Immunotherapy

  Life Sciences Jobs   ...

Walmart and Sam's Club to Offer Flu Shots In More Than 4,100 Stores and Clubs Across U.S.

BENTONVILLE, Ark., Sept. 1, 2011 /PRNewswire/ -- Walmart and Sam's Club announced today that flu shot clinics offered by Mollen Immunization Clinics are now available in more than 4,100 select stores and clubs nationwide.  The cost of the flu shots will be $25*.  Mollen will accept Medicare Part B and many other forms of private health insurance. New guidelines from the Centers for Disea...

Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb

But the two big pharma companies are enemies in the oncology and immunology arenas. How do these collaborators and competitors compare for investors? Here's how Pfizer and Bristol-Myers Squibb stack up against each other.

Jounce Therapeutics Inc JNCE Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 28082017] Prices from USD $250

SummaryJounce Therapeutics Inc Jounce is a biotechnology company. The company concentrates on the discovery and development of cancer immunotherapies, which enable the patient's immune system to search for and attack cancerous cells and tumors. Its lead candidate ICOS is an agonist monoclonal antibody which stimulates T effector cells to enhance antitumor activity. It harnesses its proprietary pro...

#jobs #lifescience Seltek Consultants: Sales | Molecular, Cell & Immunology | North UK

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Seltek Consultants: Sales | Molecular, Cell & Immunology | North UK . Up to £40K & benefits (£48K OTE/Package): Seltek Consultants: This company does not focus on KPIs, … Continue reading → Cet article #jobs #lifescience Seltek Consultants: Sa...

Global Immunology Partnering 20102017: Deal trends, players and financials [Report Updated: 01092017] Prices from USD $2995

Global Immunology Partnering 2010 to 2017 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in Immunology partnering dealsFinancial deal terms for headline, upfront and royalty by stage of developmentImmunology partnering agreement structureImmunology partnering contract documentsTop Immunology deals by...

Quick Search
Advertisement
 

review and buy Immunology market research data and corporate reports here